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Recommendations 
 
1. Clean ulcers regularly with clean water or saline, debride them when possible in order 
to remove debris from the wound surface and dress them with a sterile, inert dressing 
in order to control excessive exudate and maintain a warm, moist environment in 
order to promote healing. (GRADE strength of recommendation: Strong; Quality of 
Evidence: Low) 
 
2. In general remove slough, necrotic tissue and surrounding callus with sharp 
debridement in preference to other methods, taking relative contra-indications such as 
severe ischemia into account. (Strong; Low) 
 
3. Select dressings principally on the basis of exudate control, comfort and cost. (Strong; 
Low) 
 
4. Do not use antimicrobial dressings with the goal of improving wound healing or 
preventing secondary infection. (Strong; Moderate) 
 
5. Consider the use of systemic hyperbaric oxygen therapy, even though further blinded 
and randomised trials are required to confirm its cost-effectiveness, as well as to 
identify the population most likely to benefit from its use. (Weak; Moderate) 
 
6. Topical negative pressure wound therapy may be considered in post-operative wounds 
even though the effectiveness and cost-effectiveness of the approach remains to be 
established. (Weak; Moderate) 
 
7. Do not select agents reported to improve wound healing by altering the biology of the 
wound, including growth factors, bioengineered skin products and gases, in 
preference to accepted standards of good quality care. (Strong; Low) 
 
8. Do not select agents reported to have an impact on wound healing through alteration 
of the physical environment, including through the use of electricity, magnetism, 
ultrasound and shockwaves, in preference to accepted standards of good quality care. 
(Strong; Low) 
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9. Do not select systemic treatments reported to improve wound healing, including drugs 
and herbal therapies, in preference to accepted standards of good quality care. 
(Strong; Low) 
 
4 
 
Introduction 
There is a clear need for evidence to substantiate the use of particular interventions in the 
management of chronic ulcers of the foot in diabetes. Following the completion of the latest 
of three systematic reviews undertaken over the last ten years for the International Working 
Group on the Diabetic Foot (IWGDF) (1-3), the authors have formulated guidance on the use 
of interventions to enhance the healing of foot ulcers in diabetes, based on the evidence from 
all three reviews. The guidance is based on the GRADE system of rating both the quality of 
the evidence and the strength of the recommendations
1
. Recommendations can be made to 
support an intervention, but also against the use of a particular intervention if there is no 
strong supporting evidence to justify its adoption. The guidance is divided into ten categories 
– the same as those used to group different types of intervention in the systematic reviews. 
 
 
                                                
1
 Recommendations in this guidance were formulated based on the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system for grading evidence when writing a clinical guideline (4,5). For 
much of the older data found in the systematic review underlying this guidance we could not calculate or assess 
for inconsistency, indirectness or imprecision, which are needed to fully assess the quality of evidence. 
Therefore, we decided to assess the quality of evidence on: the risk of bias of included studies, effect sizes, and 
expert opinion, and rate the quality of evidence as ‘high’, ‘moderate’, or ‘low’. We assessed the strength of each 
recommendation as ‘strong’ or ‘weak’, based on the quality of evidence, balance between benefits and harms, 
patient values and preferences, and costs (resource utilization). The rationale behind each recommendation is 
described in this guidance. 
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Recommendations of specific types of ulcer treatment in the management of diabetic 
foot ulcers (excluding off-loading) 
 
What is the best way of debriding a diabetic foot ulcer? 
1. Clean ulcers regularly with clean water or saline, debride them when possible in order 
to remove debris from the wound surface and dress them with a sterile, inert dressing 
in order to control excessive exudate and maintain a warm, moist environment in 
order to promote healing. (GRADE strength of recommendation: Strong; Quality of 
Evidence: Low) 
2. In general remove slough, necrotic tissue and surrounding callus with sharp 
debridement in preference to other methods, taking relative contra-indications such as 
severe ischemia into account. (Strong; Low) 
 
The term debridement is here defined as the removal of surface debris, slough, necrotic and 
infected matter with the aim of leaving clean, viable tissue. Even though professional opinion 
is united in support of the use of debridement to clean the surface of the wound when 
possible, the experimental evidence to justify debridement in general and of any particular 
method of debridement, is not strong. Debridement may be undertaken using physical (eg 
surgical, sharp or hydro-debridement), biological (larvae), autolytic (hydrogels) or 
biochemical (enzymes) methods. There is surprisingly little evidence on sharp or surgical 
debridement with only a single paper included in one of the previous systematic reviews and 
that being a subgroup analysis from another trial (6). Despite this the majority of national 
guidelines emphasise that sharp debridement (7,8,9) is an essential part of good wound care, 
taking relative contra-indications such as severe ischemia into account.  
 
The available evidence from the three systematic reviews undertaken by the IWGDF, as 
published earlier in this journal, suggest that the use of hydrogels (10,11,12) as a means of 
debridement may have some benefit in terms of wound healing when compared to saline 
moistened gauze, but the risk of bias in the published studies was high – a conclusion 
supported by a Cochrane review (13). Similarly, the use of enzymatic or hydro-debridement 
cannot be supported by the available evidence, which is limited to one study on each method 
that qualified for inclusion (14,15). The use of larval therapy is equally unsupported in these 
three reviews with only four small studies identified, each of which had a high risk of bias 
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(16-19). Of interest, two recent large RCTs of the use of larval therapy in venous leg ulcers 
have failed to demonstrate benefit in terms of healing (20,21).  
 
This does not mean that debridement is ineffective but simply that the studies have not been 
done that provide robust evidence to support a strong recommendation. In general, however, 
clinicians should not adopt newer, more expensive, interventions unless they have been 
shown to have a greater impact on wound healing than existing methods.  
 
What is the best dressing to use? 
3. Select dressings principally on the basis of exudate control, comfort and cost. (Strong; 
Low) 
4. Do not use antimicrobial dressings with the goal of improving wound healing or 
preventing secondary infection. (Strong; Moderate) 
 
The three systematic reviews performed have looked at a number of different topical 
preparations designed to improve the healing of ulcers of the foot in diabetes. In general, the 
evidence to support the adoption of any particular intervention is poor, because the available 
studies are small and at high risk of bias. 
  
The results of an earlier positive study on a carboxymethycellulose dressing (22) were not 
born out by a more recent large single blind RCT with low risk of bias (23).  
There is increasing interest in the use of surface antiseptics or antimicrobials and although 
healing may not be the most obvious outcome measure to evaluate these agents, it is 
important that it is assessed in order to demonstrate the contribution it may make to the 
healing process. A single study reporting the use of antibiotic beads after transmetatarsal 
amputation found that this intervention had no impact on the incidence of wound healing 
(24).   
 
Honey has been used for centuries as an antimicrobial agent and its appeal as a potential 
target for the management of chronic wounds is obvious. There is, however, little evidence to 
support its use for either the promotion of healing or the prevention of secondary infection. 
Over the three systematic reviews, only three small controlled studies on the use of honey 
were identified and none showed convincing evidence of benefit when compared with an 
iodine-containing dressing (25-27). A Cochrane review of honey based dressings in all 
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wound types (28) concluded that health services may wish to consider avoiding routine use of 
honey dressings until sufficient evidence of effect is available – a conclusion that is endorsed 
by the results of the current review. 
 
Other topical antimicrobials, such as silver or iodine based dressings and applications, are 
also used frequently. Only one controlled trial of a silver based dressing was identified in all 
three systematic reviews (29) and this demonstrated no convincing evidence of benefit. 
Similarly, a recent Cochrane review found no evidence of benefit from the use of antiseptic 
preparations in terms of either healing or secondary infection in any studies of infected or 
contaminated wounds (30). Similarly a single large high scoring multicentre RCT which 
compared a non-adherent dressing with an iodine impregnated dressing and a 
carboxymethylcellulose hydrofibre dressing was reported in the 2012 review. This showed no 
difference between the three products either in terms of wound healing or the incidence of 
new infection (23).  
The conclusion for the whole group of topical interventions is that there was either 
insufficient or no evidence to justify the use of any of the preparations considered in 
preference to any other. In the absence of any specific indication, practitioners should use the 
dressing/application with the lowest acquisition cost, but which supports moist wound 
healing whilst controlling any exudate. 
 
 
Does systemic hyperbaric oxygen therapy (HBOT) hasten wound healing in diabetic foot 
ulcers?  
5. Consider the use of systemic hyperbaric oxygen therapy, even though further blinded 
and randomised trials are required to confirm its cost-effectiveness, as well as to 
identify the population most likely to benefit from its use. (Weak; Moderate) 
 
In our systematic reviews we reported two RCTs (31,32) of methodologically good quality on 
systemic HBOT. The larger study (32), which included patients both with and without 
(severe) peripheral arterial disease, demonstrated a significantly improved outcome in the 
intervention group, who were more likely to heal within 12 months. In a post-hoc analysis 
ulcer healing in the patients treated with HBOT was associated with baseline trans cutaneous 
oxygen pressure (TcPO2) levels, but not with ankle:brachial index (ABI) or toe blood 
pressure (33). Of note, the second RCT that also observed improved wound healing (31) 
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included only patients with non-reconstructable critical limb ischemia. It remains therefore to 
be determined which group of patients will benefit most from systemic HBOT. This is 
underscored by a large retrospective cohort study of patients treated in 83 centres located in 
31 states of the USA (34). Data were included if patients had been treated according to 
reimbursement guidelines from Centers for Medicare and Medicaid Services which require 
that patients have “an adequate lower-extremity arterial flow” as determined by the clinician. 
Using propensity score–adjusted models, the authors concluded that HBOT did not appear to 
be useful for the prevention of amputation and did not improve the likelihood that a wound 
would heal in these patients. Although the design and inclusion criteria of this study have 
been criticised, it highlights the need for further studies to determine which patient group 
might benefit most from this treatment and to establish cost-effectiveness.  
 
Does topical negative pressure wound therapy (NPWT) hasten healing in diabetic foot 
ulcers? 
6. Topical negative pressure wound therapy may be considered in post-operative wounds 
even though the effectiveness and cost-effectiveness of the approach remains to be 
established. (Weak; Moderate) 
 
NPWT is a technique for applying continuous or intermittent negative pressure to wounds via 
a material that fills the wound. Optimal use of this technique requires knowledge of the 
influence of different pressure levels, the different materials that can be put in the wound and 
the interface materials (those in direct contact with the wound surface). One theory behind 
the use of NPWT is that by extracting wound exudate, the frequency of dressing changes can 
be reduced and, wounds can therefore be kept cleaner, and with reduced malodour. 
Moreover, NPWT appears to stimulate granulation tissue formation (35,36) and contraction 
of the wound (35). It is also suggested that NPWT may increase tissue perfusion by 
mechanical means and may also encourage off-loading by making ambulation difficult (35). 
NPWT is generally useful in stimulating the healing process, but does not result in complete 
epithelialisation. Potential adverse effects of NPWT have been described, including wound 
maceration, retention of dressings and wound infection (36). A number of other potential 
contraindications to its use have been listed elsewhere (37). Given the relative complexity of 
this technique and its risks, it requires skills and organization. 
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There are two distinct types of wounds in which NPWT has been studied in the management 
of ulcers of the foot in diabetes; the post surgical and the chronic non-surgical wound. 
 
Post surgical wounds: 
In earlier systematic reviews we reported on two large RCTs  and a small RCT which 
suggested in post-operative wounds a significant benefit of NPWT in both the time to healing 
and the proportion of wounds healed (38,39,40). However, there were methodological issues 
in these studies rendering them subject to bias. 
 
One small study was reviewed in the latest review which compared the use of NPWT on the 
success of split skin grafting (41). Although apparently improving the number of split skin 
grafts which took successfully when compared to usual care, the study was of poor 
methodological quality. A small randomised but single blind study has shown that the 
qualitative but not quantitative assessment of the graft take improved when NPWT was used 
in addition to split skin grafting (42) but this was not undertaken in diabetic foot ulcers. 
 
Non-surgical ulcers: 
Three small RCTs and one cohort study have been identified on the use of NPWT in chronic 
DFUs from all three systematic reviews (43-46). All had methodological flaws but showed 
NPWT was associated with decreased wound volume and depth (43), and decreased time to 
ulcer healing (44), but these studies were subject to bias and there is, in addition, considerable 
publication bias in this area (35). It is not possible to make a recommendation on the use of 
NPWT in non-surgical wounds because of the lack of available evidence.  
 
Is there a place for the use of other topically applied treatments?  
7. Do not select agents reported to improve wound healing by altering the biology of the 
wound, including growth factors, bioengineered skin products and gases, in 
preference to accepted standards of good quality care. (Strong; Low) 
 
Four studies of collagen/oxidised regenerated cellulose dressing were identified in the three 
systematic reviews (47-50). The largest of these failed to show an effect on healing (49). 
Small, poor quality studies have reported the use of an acellular dermal regenerative matrix 
and an acellular bioproduct from pig intestine but they provided no good data to support the 
use of these products in routine care (51-53).  
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The latest search also identified a single study of perilesional injections of 
polydeoxyribonucleotide (54). Although a high scoring RCT, there are concerns about the 
poor healing rate in the control arm, the lack of detail concerning offloading and lack of 
health economic data. Earlier reports have suggested promise of some other agents (acellular 
bioproduct derived from the porcine small intestinal submucosa, acellular dermal 
regenerative tissue matrix, talactoferrin, chrysalin) that alter wound biochemistry and cell 
biology. The studies identified have provided no firm evidence to justify the use of any 
intervention listed.  
 
Platelet concentrates and platelet derived growth factors have been of interest as a therapeutic 
target for a number of years. The earliest study identified was of autologous platelet factor 
(55) but was limited by being undertaken in both leg and foot ulcers and not all patients had 
diabetes. A later study on platelet concentrate (56) reported an apparent improvement in 
wound healing but was marred by a high number of drop-outs and the use of per protocol 
analysis. The problem of the volume of blood required for the preparation of autologous 
platelet gel or fluid was overcome in a later RCT by the use of blood bank derived platelets 
(57). Although the study reported positive results, few details were provided on study 
inclusion criteria. As this product was used in uninfected, non-ischemic, non-necrotic 
wounds, this represents a minority of patients with foot ulcers. In addition, the use of non-
autologous platelets is potentially associated with adverse effects such as infection. 
 
The use of recombinant platelet derived growth factor has also been assessed. Six RCTs were 
identified (58-63) that either showed no improvement in healing between intervention and 
control groups or were marred by significant methodological problems.  Given the cost of the 
product, firm data are required for both its effectiveness and its cost effectiveness before it is 
considered for use in routine care.  
 
Other recombinant growth factors have also been the subject of studies, and these include 
basic fibroblast growth factor (bFGF), epidermal growth factor vascular endothelial growth 
factor. Two studies of bFGF (64,65) do not support the use of this agent in clinical practice. 
Despite the widespread use of EGF in some countries, only three moderately to high scoring 
RCTs have been identified, with conflicting results (66-68). Hence no clear outcomes in 
terms of healing or area reduction have been demonstrated. One study of intramuscular 
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injections of a plasmid containing the gene for vascular endothelial growth factor (69), has 
shown some promising results on reduction in wound area but needs confirmation before this 
therapy could be recommended in clinical practice. There is currently little evidence to 
suggest that any single growth factor should be considered for adoption in the management of 
foot ulcers that fail to heal with standard good care.  
 
Several early studies of cultured dermal fibroblasts, keratinocytes or fibroblast/keratinocyte 
co-culture were marred either by methodological problems or by low healing rates in the 
control groups (70-74). Only one well designed RCT later reported a significant improvement 
in healing in a group of patients who were otherwise well managed (75) but the trial was 
stopped prematurely and the result is that the effectiveness and cost effectiveness of this type 
of therapy remains to be confirmed. One promising study of co-cultured keratinocytes in 
combination with fibroblasts followed by epidermal tissue engineered autograft (76) requires 
confirmation. There are several concerns related to these products such as the complex 
application process, costs as well as suboptimal quality of the skin after healing and the 
potential of (slow-virus). For this reason we feel that higher level of evidence is needed to 
justify its routine use. Split skin grafting is widely used for various kinds of non-infected, 
non-ischemic, non-necrotic wounds, including diabetic foot ulcers. Surprisingly, only one 
study of split skin grafting (77) has been identified which for methodological reasons does 
not provide support for the use of split skin grafting to improve healing of diabetic foot 
ulcers.  
 
The evidence to justify the use of the various products available has been well reviewed in 
the three earlier IWGDF reviews, as published earlier, and the evidence to justify the use of 
any is inconclusive. It is for this reason that the routine use of any such product is not 
currently recommended.  
 
Is there a place for other local therapies to improve wound healing in the diabetic foot? 
8. Do not select agents reported to have an impact on wound healing through alteration 
of the physical environment, including through the use of electricity, magnetism, 
ultrasound and shockwaves, in preference to accepted standards of good quality care. 
(Strong; Low) 
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Studies on the use of electrical stimulation (78-80), ultrasound (81), normothermic therapy 
(82), magnetism (83) and laser therapy (84) have reported no convincing evidence of benefit. 
Reports of apparent superiority of shockwave therapy over HBO treatment are marred by the 
use of per protocol analysis and other methodological problems (85,86). There is no evidence 
to justify the recommendation for the adoption of any reported physical therapies in routine 
practice. 
 
Is there a place for other systemic therapies, including drugs and herbal therapies, in 
improving wound healing in the diabetic foot?    
9. Do not select systemic treatments reported to improve wound healing, including drugs 
and herbal therapies, in preference to accepted standards of good quality care. 
(Strong; Low) 
 
Trials of low molecular weight heparin (87), iloprost infusion (88), and of herbal preparations 
– (administered orally in two studies and intravenously in one) (89-91) were of poor quality 
and none showed any major improvement in outcome. One recent study of the use of oral 
vildagliptin (92), reported apparent improvement in healing at 12 weeks in one recent study 
but the very low incidence of healing in the control group casts doubt on the likely clinical 
benefit of this product if used in addition to good clinical care. There is no evidence to justify 
the recommendation for the adoption of any other systemic therapy to enhance the healing of 
DFUs in routine practice. 
 
Considerations  
Our recommendations are derived from critical systematic review of all relevant publications 
but this process has its limitations and these must be borne in mind. The first is that the 
reviews sought evidence specifically that an intervention may improve healing (and only of 
foot ulcers complicating diabetes – and not of other wounds, whether acute or chronic). As, 
however, the process of healing is a highly complex one, involving the interaction of many 
different cell types and signalling pathways, it is likely that the benefit of the majority of 
specific interventions is limited to a particular type of wound and to a particular phase in the 
healing process. As the process tends to last for weeks or months, this means that the impact 
of any beneficial effect of a therapy may not be apparent. It is also important to consider 
whether the benefit of a therapy has been demonstrated in people who are also receiving 
13 
 
usual best care, including adequate offloading in those with ulcers on weight bearing areas of 
the foot.  
 
If, however, studies are of insufficient duration to assess complete healing of an ulcer as an 
outcome measure, it may be possible to use a surrogate measure – such as percentage 
reduction in wound area over four weeks, which has been shown to correlate with, and to be 
predictive of, the incidence of eventual healing (93). The adoption of such a surrogate 
measure will reduce the chance of a short term response to an intervention being obscured by 
the complexity of the overall healing process. Demonstration of benefit in such short duration 
studies could then be used as the foundation for further work designed to determine the 
specific population and circumstances in which the use of the intervention is likely to be 
beneficial.  
 
Ultimately, however, the clinical endpoint of care is to accelerate complete healing of chronic 
ulcers of the foot in diabetes and this must be demonstrated if any treatment is to be generally 
recommended. Hitherto, such recommendation has not been possible because of the 
limitations both in extent and, in many cases, in quality of reported studies.  
 
KEY UNRESOLVED ISSUES 
 
1.   Overall low evidence base for the assessment of interventions 
With the exception of off-loading (not considered in this review), the field remains blighted 
by the poor level of evidence to justify the use of any particular therapy in the management of 
ulcers. There is little evidence that the number of high-quality studies is increasing.  
 
2.   The contribution made by difficulties of trial design in the continuing low output of high 
quality research in the field 
One particular aspect of trial design may be having a major impact on the poor evidence base 
for specific interventions and this relates to the choice of outcome measure for intervention 
studies. The difficulty derives from the fact that the best measure of efficacy of an 
intervention in this field is the demonstration of an effect on ulcer healing, and yet ulcer 
healing may take many weeks. If, however, an intervention is only effective at a particular 
stage of wound healing or under a particular set of clinical circumstances, then it is difficult 
to demonstrate its benefit in a conventionally designed trial. 
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3.   Very few data on effectiveness and cost-effectiveness 
Even though there are a small number of studies suggesting efficacy of particular 
interventions, there are very few studies confirming effectiveness (and, thereby, of cost-
effectiveness) of any particular intervention in routine care.  
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